Displaying 1 - 20 of 22
| Active Ingredient | COPPER-T |
| Therapeutic Class | CONTRACEPTIVES |
| Indications | Intrauterine devices (IUDs) are small contraceptive devices that are inserted into the uterus (womb) to prevent pregnancy. |
| Caution | Abdominal pain lower; anaemia; back pain; device complications; menstrual cycle irregularities; pelvic inflammatory disease; uterine injuries. |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | CYPROTERONE | ETHINYL ESTRADIOL |
| Therapeutic Class | CONTRACEPTIVES |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | DROSPIRENONE | ETHINYL ESTRADIOL |
| Therapeutic Class | CONTRACEPTIVES |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | ETHINYL ESTRADIOL | DROSPIRENONE |
| Therapeutic Class | CONTRACEPTIVES |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | ETHINYL ESTRADIOL | GESTODENE |
| Therapeutic Class | CONTRACEPTIVES |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | LEVONORGESTREL |
| Therapeutic Class | CONTRACEPTIVES |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | LYNESTRENOL |
| Therapeutic Class | CONTRACEPTIVES |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | MEDROXYPROGESTERONE |
| Therapeutic Class | CONTRACEPTIVES |
| Indications | Long-acting contraceptive. |
| Caution | Fluid retention, weight changes. |
| Dose Range | 150mg every 12 weeks for contraception. The first injection for contraception must be given ONLY during the first 5 days of a normal menstrual period, ONLY within the first 5-days postpartum if not breast feeding; and if exclusively breastfeeding |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | CONDOM |
| Therapeutic Class | CONDOMS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | DIENOGEST | ESTRADIOL |
| Therapeutic Class | ESTROGENS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | DROSPIRENONE | ESTRADIOL |
| Therapeutic Class | ESTROGENS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | ESTRADIOL |
| Therapeutic Class | CONJUGATED EQUINE ESTROGENS |
| Indications | HRT (maybe cyclical and progestogen should be added for 10-14 days of the cycle or may be continuously combined). Prevention of post-menopausal osteoporosis and vascular disease. Atrophic vaginitis; a More ... |
| Caution | Less thromboembolic disease than semisyntheticor synthetic oestrogen, spotting, breast tenderness,chloasma, weight changes. c.f. prescribing in liver disease p. 16. |
| Dose Range | Oral: 0.5-2mg daily. Vaginal: 2-4g (0.2-0.4mg oestradiol) daily for 1-2 weeks, then increase to 1-2g/day for 1-2 weeks; then maintainance dose of 1g 1-3 times weekly for 3 weeks, then off for 1 week; then repeat cycle once vaginal mucosa has been restored |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | ESTRIOL |
| Therapeutic Class | ESTROGENS |
| Indications | Hormone repalcement therapy for the treatment of lower genitourinary tract atrophy associated with estrogen deficiency, either in female climacteric or after surgical castration, which produce vagina More ... |
| Caution | breast discomfort and pain,vagianl discharge, irrtation and itch on application sites , headache, |
| Dose Range | For |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | OESTRADIOL |
| Therapeutic Class | ESTROGENS |
| Indications | HRT (may be cyclical and progestogen should be added for 10-14 days of the cycle or may be continuously combined). Prevention of post-menopausal osteoporosis and vascular disease. Atrophic va More ... |
| Caution | Less thromboembolic disease than semisyntheticor synthetic oestrogen, spotting, breast tenderness, chloasma, weight changes. C.f. prescribing in liver disease p. 16. |
| Dose Range |
Oral: 0.5-2mg daily . Vaginal: 2-4g (0.2-0.4mg oestradiol) daily for 1-2 weeks, then increase to 1-2g/day for 1-2 weeks; then maintainance dose of 1g 1-3 times weekly for 3 weeks, then off for 1 week; then rep eat cy cle once vaginal muco |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | OESTROGENS CONJUGATED |
| Therapeutic Class | ESTROGENS |
| Indications |
Prevention of post-menopausal osteoporosis.Atrophic vaginitis; atrophic urethritis, estrogen replacement.HRT (may be cyclical and progestogen should be added for 10-14 days of the cy le or may be More ... |
| Caution |
Headache, nausea, hypertension, vaginal bleeding, weight changes. c.f. prescribing in liver disease p. 16. |
| Dose Range | Oral: 0.3-1.25mg daily .; i.v/i.m: 25mg may repeat in 6-12 hours if necessary; vaginal cream: 2-4g daily for 3 weeks, off for 1 week then repeat . Breast Cancer: 10 mg three times daily for at least 3 months. Prostate Cancer: 1.25 - 2.5mg 3 times daily . |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | CLOMIPHENE |
| Therapeutic Class | ESTROGEN AGONIST-ANTAGONIST |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | RALOXIFENE |
| Therapeutic Class | ESTROGEN AGONIST-ANTAGONIST |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | ESTRADIOL | DROSPIRENONE |
| Therapeutic Class | COMBINED PREPARATIONS FOR MENOPAUSAL SYMPTOMS |
| Indications | Symptoms due to oestrogenic deficiency ,and for the prophylaxis of postmenopausal osteoporosis in women at risk of developing fractures. |
| Caution |
Headache, dizziness, nausea, changes in bleeding patterns. Do not chew tablets, swallow whole. |
| Dose Range | 1 tablet daily. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | ESTRADIOL | NORETHISTERONE |
| Therapeutic Class | COMBINED PREPARATIONS FOR MENOPAUSAL SYMPTOMS |
| Indications | Symptoms due to oestrogenic deficiency ,and for the prophylaxis of postmenopausal osteoporosis in women at risk of developing fractures. |
| Caution |
Headache, dizziness, nausea, changes in bleeding patterns. Do not chew tablets, swallow whole. |
| Dose Range | 1 tablet daily. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | OESTRADIOL | CYPROTERONE |
| Therapeutic Class | COMBINED PREPARATIONS FOR MENOPAUSAL SYMPTOMS |
| Indications | Symptoms due to oestrogenic deficiency ,and for the prophylaxis of postmenopausal osteoporosis in women at risk of developing fractures. |
| Caution |
Headache, dizziness, nausea, changes in bleeding patterns. Do not chew tablets, swallow whole. |
| Dose Range | 1 tablet daily. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |